Drugs / AGN211745
AGN211745
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00363714 | Nov 2004 → Apr 2007 | age-related macular degeneration, choroidal neovascularization | Allergan | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00395057 | Jan 2007 → Oct 2008 | age-related macular degeneration, choroidal neovascularization | Allergan | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN211745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00363714 ↗ |
| Known as | AGN-745 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650436 ↗ |
| Known as | SIRNA-027 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650436 ↗ |
| Modality | Small interfering RNA (siRNA) | “a small interfering RNA targeting vascular endothelial growth factor receptor-1” PMID 20609706 ↗ Jul 2010 |